secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0000950170-23-034556
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes Q2 2023 revenues $617.4M, GAAP net income $237.1M on arbitration win
-----------------------------------------------------------------------------

- Total revenues $617.4M including $248.4M back royalties from Janssen arbitration; proprietary product sales up 21% YoY to $231.5M.
- GAAP net income $237.1M ($1.43 basic EPS) vs net loss $30.1M in Q2 2022; non-GAAP net income $94.3M ($0.57 EPS).
- LYBALVI net sales $47.0M (+134% YoY); VIVITROL $102.1M (+6%); ARISTADA $82.4M (+10%).
- Cash and investments $907.2M; FY 2023 financial expectations reiterated, including accretive INVEGA royalties.
- Oncology separation into Mural Oncology on track for H2 2023; Caroline Loew appointed CEO designate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/0000950170-23-034556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017023034556/alks-20230726.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-034556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer